Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

3/31/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACET alert in real time by email

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

Details of the event are as follows:

Panel: "CAR T Approaches in the Autoimmune Space"

Date: Monday, April 7, 2025

Time: 3:00 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/

Adicet Bio, Inc.

Investor and Media Contacts

Investors:

Anne Bowdidge

[email protected]

Janhavi Mohite

Precision AQ

212-362-1200

[email protected]

Media:

Kerry Beth Daly

[email protected]

Get the next $ACET alert in real time by email

Date	Price Target	Rating	Analyst
9/30/2024	$7.00	Buy	Guggenheim
9/11/2024		Buy → Neutral	H.C. Wainwright
6/27/2023		Buy → Neutral	Guggenheim
6/27/2023		Mkt Outperform → Mkt Perform	JMP Securities
6/1/2023	$20.00 → $6.00	Overweight → Neutral	JP Morgan
9/21/2022	$23.00	Overweight	JP Morgan
3/31/2022	$28.00	Outperform	SMBC Nikko
3/8/2022	$30.00	Buy	Truist Securities

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Chat with this insight

Recent Analyst Ratings for
$ACET

$ACET
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Klickstein Lloyd was granted 5,900 shares, increasing direct ownership by 6% to 108,566 units (SEC Form 4)

Director Chodakewitz Jeffrey was granted 5,900 shares, increasing direct ownership by 50% to 17,700 units (SEC Form 4)

Director Dubin Steve was granted 5,900 shares, increasing direct ownership by 35% to 22,700 units (SEC Form 4)

$ACET
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)

$ACET
Press Releases

Fastest customizable press release news feed in the world

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Chat with this insight

Recent Analyst Ratings for $ACET

$ACET Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Klickstein Lloyd was granted 5,900 shares, increasing direct ownership by 6% to 108,566 units (SEC Form 4)

Director Chodakewitz Jeffrey was granted 5,900 shares, increasing direct ownership by 50% to 17,700 units (SEC Form 4)

Director Dubin Steve was granted 5,900 shares, increasing direct ownership by 35% to 22,700 units (SEC Form 4)

$ACET Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)

$ACET Press Releases

Fastest customizable press release news feed in the world

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Analyst Ratings for
$ACET

$ACET
Insider Trading

$ACET
Insider Purchases

$ACET
Press Releases